-
2024-519875-24-00
5
2025-09-26
Carcinoid syndrome
-
2024-511989-36-00
5
2025-09-24
Ewing Sarcoma
-
2025-520672-26-00
9
2025-09-16
Gastrointestinal Neoplasms
-
2024-511663-28-00
6
2025-09-11
Asymptomatic Child-Pugh A5 to B8 cirrhosis
-
2024-513171-41-00
5
2025-09-11
Vitiligo
-
2024-512752-38-00
5
2025-09-09
Adjunctive and maintenance treatment to HCT
-
2024-513955-34-00
9
2025-09-09
Proven pathogenic or probably pathogenic TBR1 variant
-
2024-518325-15-00
5
2025-09-08
Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
-
2024-519152-82-00
5
2025-09-03
Relapsed/Refractory Follicular Lymphoma
-
2024-514954-63-00
9
2025-08-20
RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS
-
2024-515875-36-00
4
2025-08-18
Advanced biliary tract cancer (BTC)
-
2023-507071-21-01
1
2025-08-14
Relapsed/Refractory Multiple Myeloma
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)
-
2023-503184-42-00
6
2025-07-28
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
-
2023-504847-15-00
5
2025-07-21
vaso-occlusive crisis due to sickle cell disease
-
2024-511667-28-00
1
2025-07-21
Plasma cell myeloma refractory
-
2024-512981-33-00
4
2025-07-09
Metastatic Colorectal Cancer
-
2024-516418-39-00
5
2025-07-09
Multiple Myeloma
-
2024-516780-93-00
5
2025-07-09
Sustained immunosuppression
-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2024-519964-42-00
3
2025-07-02
Thrombocythaemia
-
2024-518771-66-00
9
2025-07-01
Hepatoblastoma, Rhabdomyosarcoma
-
2023-508132-65-00
4
2025-06-30
NEUROENDOCRINE CELLS HYPERPLASIA OF INFANCY
-
2024-512653-25-00
5
2025-06-26
IgA nephropathy